Tissue Regenix reports record revenues and positive EBITDA for 2023
LONDON: Tissue Regenix Group (AIM: TRX), a pioneer in regenerative medical devices, has reported its audited final results for the year ending December 31, 2023. The company has achieved record revenues and, for the first time, a positive adjusted EBITDA for the full year. Financial Milestones: The company has seen a top-line revenue growth of…